In hepatocellular carcinoma (HCC) xenografts, B029-2 efficiently inhibited the HAT activity of p300/CBP, leading to decrease the expression of cyclin D1 and epigenetic alteration of H3K27ac and H3K18ac. Here, EP300 is linked to hepatocellular carcinoma.